PH17018A - Myotonolitic use of 4,5,6,7-tetrahydro-isooxazolo(5,4-c)pyridin-3-ol and derivatives thereof - Google Patents

Myotonolitic use of 4,5,6,7-tetrahydro-isooxazolo(5,4-c)pyridin-3-ol and derivatives thereof

Info

Publication number
PH17018A
PH17018A PH26130A PH26130A PH17018A PH 17018 A PH17018 A PH 17018A PH 26130 A PH26130 A PH 26130A PH 26130 A PH26130 A PH 26130A PH 17018 A PH17018 A PH 17018A
Authority
PH
Philippines
Prior art keywords
myotonolitic
isooxazolo
pyridin
tetrahydro
derivatives
Prior art date
Application number
PH26130A
Other languages
English (en)
Inventor
Hill Ronald Charles
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of PH17018A publication Critical patent/PH17018A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PH26130A 1980-09-01 1981-09-01 Myotonolitic use of 4,5,6,7-tetrahydro-isooxazolo(5,4-c)pyridin-3-ol and derivatives thereof PH17018A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8028199 1980-09-01

Publications (1)

Publication Number Publication Date
PH17018A true PH17018A (en) 1984-05-11

Family

ID=10515772

Family Applications (1)

Application Number Title Priority Date Filing Date
PH26130A PH17018A (en) 1980-09-01 1981-09-01 Myotonolitic use of 4,5,6,7-tetrahydro-isooxazolo(5,4-c)pyridin-3-ol and derivatives thereof

Country Status (6)

Country Link
US (1) US4362731A (it)
JP (1) JPS5777618A (it)
AU (1) AU555504B2 (it)
BE (1) BE890136A (it)
IT (1) IT1138543B (it)
PH (1) PH17018A (it)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813185D0 (en) * 1988-06-03 1988-07-06 Wyeth John & Brother Ltd New method & amines used therein
EP1477183B1 (en) * 1993-12-28 2005-11-02 Allergan, Inc. Neurotoxic component of Botulinum toxin for modulating cholinergic controlled secretions
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020119168A1 (en) * 2001-02-20 2002-08-29 Rudnic Edward M. Therapeutic agent delivery
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EP1761263A1 (en) * 2004-06-29 2007-03-14 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
MX2016016136A (es) 2014-06-06 2017-07-05 Ovid Therapeutics Inc Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
IL305342A (en) 2015-07-17 2023-10-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
AU2017311412B2 (en) 2016-08-11 2023-05-18 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
JP2022501384A (ja) 2018-09-20 2022-01-06 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. トゥレット症候群、チックおよび吃音の処置のためのガボキサドールの使用
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CA3123876A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc A canceled gaboxadol ring and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
JPS5777618A (en) 1982-05-15
US4362731A (en) 1982-12-07
IT1138543B (it) 1986-09-17
AU555504B2 (en) 1986-09-25
BE890136A (fr) 1982-03-01
IT8123700A0 (it) 1981-08-31
AU7478181A (en) 1982-03-11

Similar Documents

Publication Publication Date Title
PH17018A (en) Myotonolitic use of 4,5,6,7-tetrahydro-isooxazolo(5,4-c)pyridin-3-ol and derivatives thereof
JPS57150688A (en) Furo(3,4-c)pyridine derivative, manufacture and medicinal composition containing same
DE3171325D1 (en) Tridecyloxy- or tetradecyloxy-propane derivatives, and their use
PH17019A (en) 4-piperidyl-or dehydropiperidyl-urea derivatives and method of use
IL61930A0 (en) 25-hydroxy-26,26,26,27,27,27-hexafluoroch-olecalciferol and derivatives thereof
DE3163926D1 (en) Process for the preparation of anthraquinone and its substituted derivatives
IL59829A (en) Derivatives of 9,10-anthracene-bis-carboxaldehyde-bis-hydrazone
DE3367931D1 (en) Preparation of 1,4-diketopyrrolo-(3,4-c)-pyrroles
IL64146A0 (en) Derivatives of thieno-pyridinone,the method of their preparation and their therapeutic use
GB2087383B (en) Preparation of 1,1,1,3,3,-hexafluoropropane-2-ol
JPS56169632A (en) Manufacture of 2-chloro-1,1,1,2,3,3,3- heptafluoropropane
IL63282A0 (en) Benzenosulfonamide derivatives and their use as herbicides
GB2118554B (en) N-carbamoyl derivatives of isothiazolo (5,4b)-pyridin-3-one
DE3160724D1 (en) N'-phenyl-n-methylurea derivatives, their production and use
GB2031426B (en) Imidazo(2',1':2,3)thiazolo(5,4-c)pyridines and related compounds
DE3362345D1 (en) Mixtures of specific 1,2-cycloaliphatic diepoxydes, and use thereof
EG16504A (en) Derivatives of 5,6,7,7,a-tetrahydro-4h-thieno(3,2-c)pyridin 2-one and the preparation thereof
IL63061A (en) 6-arylhydrazono-pyrido(2,1-b)quinazoline-11-ones and their preparation
IL62808A (en) Aralkylaniline derivatives and their use as herbicides
JPS56161367A (en) Manufacture of 3-mercapto-propanediol-(1,2)
GB2084578B (en) Coumarinyl-7 and 3,4-benzo coumarinyl-7 derivatives
PH14037A (en) New 2-phenyl-5,6-dihydro-4-pyrone derivatives and herbicidal composition
ZA828471B (en) Herbicidal preparations containing thiazolo-and(1,3)thiazino-(2,3-c)(1,2,4)-triazinones and the manufacture of these compounds
DE3167861D1 (en) Preparation of alpha-chlorinated nitrogen heterocycles
JPS56139485A (en) 4-alpha-cycloamino-arylmethyl-6-methyl- 1,3-dihydro-flo(3,4-c)-pyridine-7-ol, manufacture and use